Atezolizumab in Urothelial Bladder Carcinoma

References

• Antoni S , FerlayJ, SoerjomataramI, ZnaorA, JemalA, BrayF. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol.71(1), 96–108 (2017).
   PubMed Web of Science ®Google Scholar
• Stein JP , LieskovskyG, CoteRet al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol.19(3), 666–675 (2001).
   PubMed Web of Science ®Google Scholar
• Burger M , CattoJW, DalbagniGet al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol.63(2), 234–241 (2013).
   PubMed Web of Science ®Google Scholar
• Miyazaki J , NishiyamaH. Epidemiology of urothelial carcinoma. Int. J. Urol.24(10), 730–734 (2017).
   PubMed Web of Science ®Google Scholar
• von der Maase H , SengelovL, RobertsJTet al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol.23(21), 4602–4608 (2005).
   PubMed Web of Science ®Google Scholar
• Alfred Witjes J , LebretT, CompératEMet al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol.71(3), 462–475 (2017).
   PubMed Web of Science ®Google Scholar
• Sternberg CN , de MulderPH, SchornagelJHet al. Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol.19(10), 2638–2646 (2001).
   PubMed Web of Science ®Google Scholar
• Lorusso V , PolleraCF, AntimiMet al. A Phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur. J. Cancer34(8), 1208–1212 (1998).
   PubMed Web of Science ®Google Scholar
• Papamichael D , GallagherCJ, OliverRTet al. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. Br. J. Cancer75(4), 606–607 (1997).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , ThéodoreC, Demkovet al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J. Clin. Oncol.27(27), 4454–4461 (2009).
   PubMed Web of Science ®Google Scholar
• Galsky MD , HahnNM, RosenbergJet al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol.12(3), 211–214 (2011).
   PubMed Web of Science ®Google Scholar
• De Santis M , BellmuntJ, MeadGet al. Randomized Phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: Phase II – results of EORTC study 30986. J. Clin. Oncol.27(33), 5634–5639 (2009).
   PubMed Web of Science ®Google Scholar
• Barone A , HazarikaM, TheoretMRet al. FDA approval summary: pembrolizumab for the treatment of patients with unresectable or metastatic melanoma. Clin. Cancer Res.23(19), 5661–5665 (2017).
   PubMed Web of Science ®Google Scholar
• Sul J , BlumenthalGM, JiangX, HeK, KeeganP, PazdurR. FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist21(5), 643–650 (2016).
   PubMed Web of Science ®Google Scholar
• Larkins E , BlumenthalGM, YuanWet al. U.S. Food and Drug Administration approval summary: pembrolizumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy. Oncologist22(7), 873–878 (2017).
   PubMed Web of Science ®Google Scholar
• Kasamon YL , KasamonYL, de ClaroRAet al. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. Oncologist22(5), 585–591 (2017).
   PubMed Web of Science ®Google Scholar
• Xu JX , MaherVE, ZhangLet al. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist22(3), 311–317 (2017).
   PubMed Web of Science ®Google Scholar
• Ning YM , SuzmanD, MaherVEet al. FDA approval summary: atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy. Oncologist22(6) 743–749 (2017).
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G , GlickmanMS, BochnerBH. The mechanism of action of BCG therapy for bladder cancer – a current perspective. Nat. Rev. Urol.11(3), 153–162 (2014).
   PubMed Web of Science ®Google Scholar
• Meng X , HuangZ, TengF, XingL, YuJ. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat. Rev.41(10), 868–876 (2015).
   PubMed Web of Science ®Google Scholar
• Zibelman M , RamamurthyC, PlimackER. Emerging role of immunotherapy in urothelial carcinoma-advanced disease. Urol. Oncol.34(12), 538–547 (2016).
   PubMed Web of Science ®Google Scholar
• Topalian SL , TaubeJM, AndersRA, PardollDM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer16(5), 275–287 (2016).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Aydin AM , WolduSL, HutchinsonRCet al. Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. Onco. Targets Ther.10, 1487–1502 (2017).
   PubMed Web of Science ®Google Scholar
• Krummel MF , AllisonJP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med.182(2), 459–465 (1995).
   PubMed Web of Science ®Google Scholar
• Ohaegbulam KC , AssalA, Lazar-MolnarE, YaoY, ZangX. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol. Med.21(1), 24–33 (2015).
   PubMed Web of Science ®Google Scholar
• Kostine M , ChicheL, LazaroEet al. Opportunistic autoimmunity secondary to cancer immunotherapy (OASI): an emerging challenge. Rev. Med. Interne38(8), 513–525 (2017).
   PubMed Web of Science ®Google Scholar
• Herbst RS , SoriaJC, KowanetzMet al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature515(7528), 563–567 (2014).
   PubMed Web of Science ®Google Scholar
• Deng R , BumbacaD, PastuskovasCVet al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs8(3), 593–603 (2016).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , PowlesT, VogelzangNJ. A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat. Rev.54, 58–67 (2017).
   PubMed Web of Science ®Google Scholar
• Powles T , EderJP, FineGDet al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature515(7528), 558–562 (2014).
   PubMed Web of Science ®Google Scholar
• Rosenberg JE , Hoffman-CensitsJ, PowlesTet al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase II trial. Lancet387(10031), 1909–1920 (2016).
   PubMed Web of Science ®Google Scholar
• Bellmunt J . IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma. Presented at: The European Society for Medical Oncology 2016 Congress.Copenhagen, Denmark, 7–11 October 2016.
   Google Scholar
• Galsky MD . Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J. Clin. Oncol.29(17), 2432–2438 (2011).
   PubMed Web of Science ®Google Scholar
• Balar AV , GalskyMD, RosenbergJEet al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, Phase 2 trial. Lancet389(10064), 67–76 (2017).
   PubMed Web of Science ®Google Scholar
• Powles T . IMvigor211: a Phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. Presented at: EACR-AACR-SIC Special Conference 2017.Florence, Italy, 24–27 June 2017.
   Google Scholar
• Loriot Y . Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): updated OS, safety and biomarkers from the Phase 2 trial. Presented at: The European Society for Medical Oncology 2016 Congress.Copenhagen, Denmark, 7–11 October 2016.
   Google Scholar
• Taube JM , KleinA, BrahmerJRet al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res.20(19), 5064–5074 (2014).
   PubMed Web of Science ®Google Scholar
• Festino L , BottiG, LoriganPet al. Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs 76(9), 925–945 (2016).
   PubMed Web of Science ®Google Scholar
• Ratcliffe MJ , SharpeA, MidhaAet al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin. Cancer Res.23(14), 3585–3591 (2017).
   PubMed Web of Science ®Google Scholar
• Nakanishi J , WadaY, MatsumotoK, AzumaM, KikuchiK, UedaS. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother.56(8), 1173–1182 (2007).
   PubMed Web of Science ®Google Scholar
• Inman BA , SeboTJ, FrigolaXet al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer109(8), 1499–1505 (2007).
   PubMed Web of Science ®Google Scholar
• Huang Y , ZhangSD, McCruddenC, ChanKW, LinY, KwokHF. The prognostic significance of PD-L1 in bladder cancer. Oncol. Rep.33(6), 3075–3084 (2015).
   PubMed Web of Science ®Google Scholar
• No authors listed. First tissue-agnostic drug approval issued. Cancer Discov.7(7), 656 (2017).
   Web of Science ®Google Scholar
• Skeldon SC , SemotiukK, AronsonMet al. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer. Eur. Urol.63(2), 379–385 (2013).
   PubMed Web of Science ®Google Scholar
• Li Q , BagrodiaA, ChaEK, ColemanJA. Prognostic genetic signatures in upper tract urothelial carcinoma. Curr. Urol. Rep.17(2), 12 (2016).
   PubMed Web of Science ®Google Scholar
• Carlo MI , ZhangL, MandelkerDet al. Cancer predisposing germline mutations in patients (pts) with urothelial cancer (UC) of the renal pelvis (R-P), ureter (U) and bladder (B). Presented at: American Society of Clinical Oncology 2017 Annual Meeting.Chicago, IL, USA, 2–6 June 2017.
   Google Scholar
• Iyer G , AudenetF, MiddhaSet al. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. Presented at: American Society of Clinical Oncology 2017 Annual Meeting.Chicago, IL, USA, 2–6 June 2017.
   Google Scholar
• Teo MY , SeierK, OstrovnayaIet al. DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). Presented at: American Society of Clinical Oncology 2017 Annual Meeting.Chicago, IL, USA, 2–6 June 2017.
   Google Scholar
• Tumeh PC , HarviewCL, YearleyJHet al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature515(7528), 568–571 (2014).
   PubMed Web of Science ®Google Scholar
• Martens A , Wistuba-HamprechtK, Geukes FoppenMet al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin. Cancer Res.22(12), 2908–2918 (2016).
   PubMed Web of Science ®Google Scholar
• Sivan A , CorralesL, HubertNet al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science350(6264), 1084–1089 (2015).
   PubMed Web of Science ®Google Scholar
• Vetizou M , PittJM, DaillèreRet al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science350(6264), 1079–1084 (2015).
   PubMed Web of Science ®Google Scholar
• NICE . NICE appraisal consultation document – atezolizumab for treating locally advanced or metastatic urothelial carcinoma (2017). www.nice.org.uk/guidance/gid-ta10111/documents/appraisal-consultation-document
   Google Scholar